Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
30 sept. 2019 16h19 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation...
Geron to Announce Second Quarter Financial Results on August 1, 2019
25 juil. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on...
Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene
28 mai 2019 10h00 HE
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, May 28, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development of female-specific oncology products, today...
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
16 mai 2019 09h05 HE
|
Geron Corporation
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s...
Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
17 avr. 2019 07h35 HE
|
Intensity Therapeutics Inc
WESTPORT, Conn., April 17, 2019 (GLOBE NEWSWIRE) -- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers...
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
08 avr. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 08, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
03 déc. 2018 06h00 HE
|
Geron Corporation
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial...
Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita
12 nov. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis
01 nov. 2018 07h00 HE
|
Constellation Pharmaceuticals , Inc.
- Recently Expanded and Enhanced MANIFEST Phase 2 Trial Ongoing with Proof of Concept Data Expected Mid-2019 CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals,...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)
13 avr. 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 13, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation...